Danaher Corporation (DHR) Analyst Ratings & Price Targets

Danaher Corporation

DHR · NYSE

Analyst Consensus

Buy

21 analysts

$199

Current

—

Low

$220

Average

—

High

Average target implies +10.60% versus the current price.

The ratings synthesis for DHR has not been generated yet.

Rating Actions

No individual rating actions have been captured for DHRyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BENCHMARK COMPA

CITIGROUP

DEUTSCHE BK SEC

EDWARD JONES

GOLDMAN SACHS

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

KEYBANC CAP MKT

LEERINK PARTNRS

RAYMOND JAMES

RBC CAPITAL

STIFEL NICOLAUS

TD COWEN

UBS

WILLIAM BLAIR

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: DHR
Type: Stock
Sector: Industrials
Industry: Industrial Machinery/Components
Country: North America
Exchange: NYSE

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges-helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

Analyst Consensus

See all

Buy